Guidance in development www.nice.org.uk
- Arthritis (juvenile idiopathic, systemic) - canakinumab [ID533]
- Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523]
- Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease
- Faecal calprotectin diagnostic tests to differentiate inflammatory bowel disease from irritable bowel syndrome
- Hyperplasia (benign prostatic) - tadalafil [ID534]
- Implementing Vitamin D guidance
- Lung cancer (non-small-cell, second line) - erlotinib and gefitinib (rev of TA162 and TA175) [ID620]
- Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
- Multiple myeloma - bortezomib (consolidation therapy) [ID529]
- Multiple myeloma - bortezomib (induction therapy) [ID610]
- Needle and syringe programmes (update)
- Obesity - phentermine (with topiramate) [ID543]
- Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91) [ID468]
- Overactive bladder - mirabegron [ID542]
- Sexually harmful behaviour among young people
- Sunlight exposure: benefits and safety
Guidance recently published by NICE www.nice.org.uk
- Adjunctive colposcopy technologies for examination of the uterine cervix - DySIS and the Niris Imaging System
- Partial replacement of the meniscus of the knee using a biodegradable scaffold
- Preventing type 2 diabetes - risk identification and interventions for individuals at high risk
- Spasticity in children and young people
- Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal)
- Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban
